Osteoarthritis and osteoporosis: What is the overlap?

Current Rheumatology Reports

Volumn 15, Issue 5, 2013, Pages

  Bultink, Irene E M ^a   Lems, Willem F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adipokines; Anti osteoporotic drugs; Bisphosphonates; Body mass index; Bone mineral density; Bone remodelling; Calcitonin; Cartilage; Cathepsin K inhibitors; Estrogen; Fracture; Inflammation; Obesity; Osteoarthritis; Osteoporosis; Overlap; Strontium ranelate; Subchondral bone; Teriparatide

Indexed keywords

ADIPOCYTOKINE; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN K INHIBITOR; CYTOKINE; ESTROGEN; ODANACATIB; OSTEOPROTEGERIN; PARATHYROID HORMONE[1-34]; PLACEBO; RANTES; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; TILUDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; ARTICULAR CARTILAGE; BODY MASS; BONE METABOLISM; BONE REMODELING; CARTILAGE DEGENERATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG MEGADOSE; FRACTURE; FRAGILITY FRACTURE; HAND OSTEOARTHRITIS; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; KNEE OSTEOARTHRITIS; KNEE PAIN; NONHUMAN; OBESITY; OSTEOARTHRITIS; OSTEOCLASTOGENESIS; OSTEOPHYTE; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RHEUMATOID ARTHRITIS; SPONDYLOSIS; UNDERWEIGHT; WEIGHT BEARING; BODY WEIGHT; COMORBIDITY; FEMALE; JOINT; MALE; MECHANICAL STRESS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; RISK FACTOR;

ADIPOKINES; COMORBIDITY; FEMALE; HUMANS; JOINTS; MALE; OBESITY; OSTEOARTHRITIS; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; RISK FACTORS; STRESS, MECHANICAL; THINNESS; WEIGHT-BEARING;

EID: 84874940947     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-013-0328-0     Document Type: Article

References (70)

1. Dequeker J, Aerssens J, Luyten FP. Osteoarthritis and osteoporosis: clinical and research evidence of inverse relationship. Aging Clin Exp Res. 2003;15:426-39. (Pubitemid 37509168)
2. Hart DJ, Mootoosamy I, Doyle DV, et al. The relationship between osteoarthritis and osteoporosis in the general population: the Chingford Study. Ann Rheum Dis. 1994;53:158-62. (Pubitemid 24123867)
3. Healey JH, Vigorita VJ, Lane JM. The coexistence and characteristics of osteoarthritis and osteoporosis. J Bone Joint Surg Am. 1985;67:586-92. (Pubitemid 15077727)
4. Lafeber FPJG, Van Laar JM. Strontium ranelate: ready for clinical use as disease-modifying osteoarthritis drug? Ann Rheum Dis. 2013;72:157-61.
5. •• Bijlsma JWJ, Berenbaum E, Lafeber FPJG. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011;377:2115-26. This is an outstanding state-of-the-art article on the epidemiology, etiology, clinical characteristics, diagnostic measures, and therapeutic options for osteoarthritis.
6. Felson DT, McLaughlin S, Goggins J, et al. Bone marrow edema and its relation to progression of knee osteoarthritis. Ann Intern Med. 2003;139:330-6.
7. Berry PA, Maciewicz RA, Cicuttini FM, et al. Markers of bone formation and resorption identify subgroups of patients with clinical knee osteoarthritis who have reduced rates of cartilage loss. J Rheumatol. 2010;37:1252-9.
8. Goldring MB, Goldring SR. Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Ann N Y Acad Sci. 2010;1192:230-7.
9. Zhang ZM, Li ZC, Jiang LS, et al. Micro-CT and mechanical evaluation of subchondral trabecular bone structure between postmenopausal women with osteoarthritis and osteoporosis. Osteoporos Int. 2010;21:1383-90.
10. Funck-Brentano T, Cohen-Solal M. Crosstalk between cartilage and bone: when bone cytokines matter. Cytokine Growth Factor Rev. 2011;22:91-7.
11. Bultink IEM, Vis M, Van der Horst-Bruinsma IE, Lems WF. Inflammatory rheumatic disorders and bone. Curr Rheumatol Rep. 2012;14:224-30.
12. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165-76. (Pubitemid 28180851)
13. •• Schett G, Saag KG, Bijlsma JWJ. From bone biology to clinical outcome: state of the art and future perspectives. Ann Rheum Dis. 2010;69:1415-9. This is an excellent state-of-the-art article on bone biology.
14. • Geusens PP, Lems WF. Osteoimmunology and osteoporosis. Arthritis Res Ther. 2011;13:242. Epub. This article is a large overview on osteoimmunology and osteoporosis.
15. Xu S, Wang Y, Lu J, Xu J. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arhritis-induced osteoporosis. Rheumatol Int. 2012;32:3397-403.
16. Schett G, Kiechl S, Weger S, et al. High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med. 2006;166:2495-501. (Pubitemid 44913235)
17. • Yusuf E, Nelissen RG, Ioan-Facsinay A, et al. Association between weight or body mass index and hand osteoarthritis: a systematic review. Ann Rheum Dis. 2010;69:761-5. This is an excellent systematic review on the association between obesity and hand osteoarthritis.
18. Hunter DJ, Felson DT. Osteoarthritis. BMJ. 2006;332:639-42. (Pubitemid 44365719)
19. Berenbaum F, Wymard F, Houard X. Osteoarthritis, inflammation and obesity. Curr Opin Rheumatol. 2013;25:114-8.
20. Filková M, Lišková M, Hulejová H, et al. Increased serum adiponectin levels in female patients with erosive compared with non-erosive osteoarthritis. Ann Rheum Dis. 2009;68:295-6.
21. Choe JY, Bae J, Jung HY, et al. Serum resistin level is associated with radiographic changes in hand osteoarthritis: cross-sectional study. Joint Bone Spine. 2012;79:160-5.
22. Yusuf E, Ioan-Facsinay A, Bijsterbosch J, et al. Association between leptin, adiponectin and resistin and long-term progression of hand osteoarthritis. Ann Rheum Dis. 2011;70:282-4.
23. Honsawek H, Chayanupatkul M. Correlation of plasma and synovial fluid adiponectin with knee osteoarthritis severity. Arch Med Res. 2010;41:593-8.
24. Koskinen A, Juslin S, Nieminen R, et al. Adiponectin associates with markers of cartilage degradation in osteoarthritis and induces production of proinflammatory and catabolic factors through mitogen-activated protein kinase pathways. Arthritis Res Ther. 2011;13:R184.
25. Berry PA, Jones SW, Cicuttini FM, Wluka AE, Maciewicz RA. Temporal relationship between serum adipokines, biomarkers of bone and cartilage turnover, and cartilage volume loss in a population with clinical knee osteoarthritis. Arthritis Rheum. 2011;63:700-7.
26. Iwamoto J, Takeda T, Sato Y, Matsumoto H. Serum leptin concentration positively correlates with body weight and total fat mass in postmenopausal Japanese women with osteoarthritis of the knee. Arthritis. 2011;2011:580632.
27. Anandacoomarasamy A, Giuffre BM, Leibman S, et al. Delayed gadolinium-enhanced magnetic resonance imaging of cartilage: clinical associations in obese adults. J Rheumatol. 2009;36:1056-62.
28. Van Spil WE, Welsing PMJ, Kloppenburg M, et al. Cross-sectional and predictive associations between plasma adipokines and radiographic signs of early-stage knee osteoarthritis: data from CHECK. Osteoarthr Cartil. 2012;20:1278-85.
29. De Laet C, Kanis JA, Odén A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005;16:1330-8. (Pubitemid 41532085)
30. Prieto-Alhambra D, Premaor MO, Fina Avilés F, et al. The association between fracture and obesity is site-dependent: a population-based study in postmenopausal women. J Bone Miner Res. 2012;27:294-300.
31. Armstrong ME, Cairns BJ, Banks E, et al. Different effects of age, adiposity and physical activity on the risk of ankle, wrist and hip fractures in postmenopausal women. Bone. 2012;50:1394-400.
32. Nielson CM, Srikanth P, Orwoll ES. Obesity and fracture risk in men and women: an epidemiologic perspective. J Bone Miner Res. 2012;27:1-10.
33. Richette P, Corvol M, Bardin T. Estrogens, cartilage, and osteoarthritis. Joint Bone Spine. 2003;70:257-62. (Pubitemid 37064580)
34. Wilson MG, Michet Jr CJ, Ilstrup DM, et al. Idiopathic symptomatic osteoarthritis of the hip and knee: a population-based incidence study. Mayo Clin Proc. 1990;65:1214-21. (Pubitemid 20332184)
35. Sniekers YH, Weinans H, Bierma-Zeinstra SM, et al. Animal models for osteoarthritis: the effect of ovariectomy and estrogen treatment - a systematic approach. Osteoarthr Cartil. 2008;16:533-41.
36. Sniekers YH, Weinans H, van Osch GJ, et al. Oestrogen is important for maintenance of cartilage and subchondral bone in a murine model of knee osteoarthritis. Arthritis Res Ther. 2010;12:R182.
37. Richette P, Dumontier MF, Tahiri K, et al. Oestrogens inhibit interleukin 1beta-mediated nitric oxide synthase expression in articular chondrocytes through nuclear factor-kappa B impairment. Ann Rheum Dis. 2007;66:345-50. (Pubitemid 46579636)
38. Bay-Jensen AC, Tabassi NC, Sondergaard LV, et al. The response to estrogen deprivation of the cartilage collagen degradation marker, CTX-II, is unique compared with other markers of collagen turnover. Arthritis Res Ther. 2009;11:R9.
39. Mouritzen U, Christgau S, Lehmann HJ, et al. Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis. 2003;62:332-6. (Pubitemid 36363439)
40. Christgau S, Tanko LB, Cloos PA, et al. Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause. 2004;11:508-18. (Pubitemid 40362149)
41. Carbone LD, Nevitt MC, Wildy K, et al. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum. 2004;11:3516-25. (Pubitemid 39488676)
42. Karsdal MA, Sondergaard BC, Arnold M, et al. Calcitonin affects both bone and cartilage: a dual action treatment for osteoarthritis? Ann N Y Acad Sci. 2007;1117:181-95. (Pubitemid 350191278)
43. Sondergaard BC, Madsen SH, Segovia-Silvestre T, et al. Investigation of the direct effects of salmon calcitonin on human osteoarthritic chondrocytes. BMC Musculoskelet Disord. 2010;11:62.
44. Manicourt DH, Azria M, Mindeholm L, et al. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum. 2006;54:3205-11. (Pubitemid 44622091)
45. Karsdal MA, Byrjalsen I, Henriksen K, et al. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritis patients: a 14-day randomized study. Osteoarthr Cartil. 2010;18:150-9.
46. Bagger YZ, Tanko LB, Alexandersen P, et al. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone. 2005;37:425-30. (Pubitemid 41160502)
47. Saag KG. Bisphosphonates for osteoarthritis prevention: "Holy Grail" or not? Ann Rheum Dis. 2008;67:1358-9.
48. Podworny NV, Kandel RA, Renlund RC, et al. Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis. J Rheumatol. 1999;26:1972-82. (Pubitemid 30007067)
49. Hayami T, Pickarski M, Wesolowski GA, et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum. 2004;50:1193-206. (Pubitemid 38480830)
50. Kadri A, Funck-Brentano T, Lin H, et al. Inhibition of bone resorption blunts osteoarthritis in mice with high bone remodeling. Ann Rheum Dis. 2010;69:1533-8.
51. Moreau M, Rialland P, Pelletier JP, et al. Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model. Arthritis Res Ther. 2011;13:R98.
52. Neogi T, Nevitt MC, Ensrud KE, et al. The effect of alendronate on progression of spinal osteophytes and disc space narrowing. Ann Rheum Dis. 2008;67:1427-30.
53. Spector TD, Conaghan PG, Buckland-Wright JC, et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial. Arthritis Res Ther. 2005;7:R625-33.
54. Bingham CO, Buckland-Wright JC, Garnero P, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symtpoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee. Arthritis Rheum. 2006;54:3493-507. (Pubitemid 44737161)
55. Buckland-Wright JC, Messent EA, Bingham CO, et al. A 2 year longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritis knee patients. Rheumatology. 2007;46:257-64. (Pubitemid 46189786)
56. Roux C, Richette P. Impact of treatments for osteoporosis on osteoarthritis progression. Osteoporos Int. 2012;23:S881-3.
57. Laslett LL, Doré DA, Quinn SJ, et al. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. Ann Rheum Dis. 2012;71:1322-8.
58. Marie PJ. Strontium ranelate: new insights into its dual mode of action. Bone. 2007;40:S5-8. (Pubitemid 46562594)
59. Alexandersen P, Karsdal MA, Qvist P, et al. Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women. Bone. 2007;40:218-22. (Pubitemid 44848419)
60. Alexandersen P, Karsdal MA, Byrjalsen I, et al. Strontium ranelate effect in postmenopausal women with different clinical levels of osteoarthritis. Climacteric. 2011;14:236-43.
61. Van Spil WE, Drossaers-Bakker KW, Lafeber FPJG. Associations of CTX-II with biochemical markers of bone turnover rise questions on its tissue origin: data from CHECK, a cohort study of early osteoarthritis. Ann Rheum Dis. 2013;72:29-36.
62. Bruyere O, Delferriere D, Roux C, et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis. 2008;67:335-9. (Pubitemid 351281267)
63. • Reginster J-Y, Badurski J, Bellamy N, et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis. 2013;72:179-86. In this article, the results of the first prospective, placebo-controlled, clinical study on the effect of strontium ranelate in the treatment of osteoarthritis (of the knee) are presented.
64. Tat SK, Pelletier J-P, Mineau F, et al. Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts. Bone. 2011;49:559-67.
65. Henrotin Y, Labasse A, Zheng SX, et al. Strontium ranelate increases cartilage matrix formation. J Bone Miner Res. 2001;16:299-308. (Pubitemid 32105411)
66. Simpson ER, Hilton MJ, Tian Y, et al. Teriparatide, a chondro-regenerative therapy for injury-induced osteoarthritis. Sci Transl Med. 2011;3:101ra93.
67. Terkeltaub R, Lotz M, Johnson K, et al. Parathyroid hormone-related proteins is abundant in osteoarthritic cartilage, and the parathyroid hormone-related protein 1-173 isoform is selectively induced by transforming growth factor beta in articular chondrocytes and suppresses generation of extracellular inorganic pyrophosphate. Arthritis Rheum. 1998;41:2152-64. (Pubitemid 29009373)
68. Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone mineral density. J Bone Miner Res. 2010;25:937-47.
69. Hayami T, Zhuo Y, Wesolowski GA, et al. Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis. Bone. 2012;50:1250-9.
70. FDA - Clinical development programs for drugs, devices and biological products intended for the treatment of OA. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances (7/99).